GQR’s Post

What it means to be disruptive and how that can be beneficial to a given industry

At #DPHARM2024, PA's experts engaged with clinical innovators to explore how we can accelerate the pace of #ClinicalTrials. Discover the insights that are pushing boundaries and redefining industry benchmarks! https://bit.ly/4gOrILZ

“Which carries more risk: participation or avoidance?” – the big question many in the corporate world face when it comes to social media.   For a highly regulated industry like #pharma, avoidance is often the easier, safer choice – but is it the most effective? Not necessarily, as convincingly articulated by Roger Christie, keynote speaker of the MedNews Aust/NZ event, “Pharma reputation: Building trust in the digital age”.   Great insights and discussions were shared on this and other themes surrounding reputation within the pharma industry, with one thought resonating with everyone in the room: in order to be trusted, you have to be liked; in order to be liked, you have to be known.   As panellist John Morton argued, it all comes down to "what’s your story, who are you trying to communicate with and for what purpose?" These are very useful parameters for the pharma industry to take stock of and drive more proactive communication on how it contributes to health, wellbeing and productivity within our societies today.

Are you heading to the Intellus Worldwide conference next month?! Our team is headed there and would love to catch up! Let us know if you're going! ⤵ #Pharma #Analytics #Consulting #Healthcare #ConsumerInsights #IntellusWW #WeAreIntellusWW #IntellusWorldWide #RecknerHealthcare

Spending on GLP-1 drugs is climbing, affecting both your diabetic and non-diabetic employees. As this trend continues, it’s important to look beyond the cost and understand the broader impact on your health plan. Innovu's software, InnovuLens, was created to help navigate the complexities of data integration and analytics in the healthcare benefits space. Read their latest Did You Know to find out more! https://lnkd.in/eBdP24An #PBGH #PBGHPA #PeopleYouTrust #InnovuLens #Data #GLP1

Our CEO, Hakim Yadi Ph.D. OBE shared his insights in part 2 of the Scrip series “Scrip Asks… What does 2024 hold for biopharma?” on the funding environment, M&A, and partnering. In this latest feature, Hakim stresses the importance of breaking away from siloed solutions, advocating for comprehensive, system-wide approaches to meet healthcare demands.   He added: “Considering the inherent global market instability, the ever-evolving landscape of medical technologies, and the surging market demands, sticking to the status quo is a surefire way to fall behind. To not only survive but thrive in 2024, businesses must embrace agility, strategy, and assertiveness. This necessitates a fundamental overhaul of outdated business models and a willingness to seek external investments that can modernize global health care to align with the shifting global needs, interests, and capabilities.”   Read the full article here: bit.ly/3Um4Ri3   #Biopharma #Healthcare #Innovation #TechBio #Scrip #Funding

Delving deeper into regulatory matters! Join me in exploring the latest insights on #RegulatoryAffairs in healthcare with Simon Maurer and the Simed Global team. 🌐✨ Every week, we unpack the intricate world of regulations impacting our industry, discussing key strategies and updates vital for ensuring compliance and innovation. 🏥💡 Don't miss out on these enlightening conversations - they're packed with actionable insights! 👨⚕️ As someone passionate about ensuring safe and effective healthcare solutions, I'm thrilled to share these discussions with you. Let's navigate this ever-evolving landscape together. Tune in and join the conversation! #HealthcareRegulations #ExpertInsights #SimedGlobal #RegulatoryMatters Your thoughts and questions are always welcome! #iso13485 #MDR #ivdr #iso10993

Healthcare providers bear a grave duty of care, but when the prognosis is poor, full disclosure allows informed choices.  Overall, our healthcare system aims to heal but is also a business - this is an uncomfortable reality. Perhaps it's time to rethink financial incentives and have open discussions on balancing various stakeholder needs, especially for vulnerable groups. Most of all, we must approach these complex issues with empathy, wisdom, and care for all people. Who are we? To learn more about us, visit divergentcro.com  #pharma #research #biotech #medical #monitoring #qualityassurance #quality #drug 

I will be speaking at #DIA2024 as part of the panel discussing “Exploiting Real World Data from Social Media in Patient-Focused Drug Development”. I look forward to discussing the topic with Thierry Escudier, Vishakha Sharma, PhD and Sarah Lyons. Patient listening on social media is a mature method to better understand patients' priorities, unmet needs and which outcomes truly matter to them. At the panel, we will discuss what challenges remain to foster mainstream adoption and maximize regulatory impact of this innovative method. We look forward to discussing with you on the panel! #patientcentricity #socialmedialistening #pfdd

Listen to our Fireside Chat with Barış Erdoğan, CEO of Clinerion, for a discussion on real-world electronic health record (EHR) data, clinical trials, and drug development acceleration: https://hubs.la/Q02JyRBL0